Trial Profile
Persistence with Etanercept or other TNFi monotherapy among rheumatoid arthritis patients who achieved remission or low disease activity on combination TNFi+csDMARD therapy: data from CORRONA registry
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Dec 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Hydroxychloroquine; Leflunomide; Methotrexate; Sulfasalazine
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 14 Jul 2018 New trial record
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism